Importantly, early administration of a TRPA1 or a TRPV1 antagonist attenuated the transition and development of experimental pancreatic inflammation and pain from acute experimental to chronic, thereby providing an effective disease-modifying therapy [121]. The gene discussed is TRPA1; the disease is inflammatory response.